Table 1. The clinicopathological features of patients with or without splenomegaly before PSM.
| Clinical variables | Splenomegaly (n=140) | Non-splenomegaly (n=576) | P |
|---|---|---|---|
| Age, year | 48.0 (32.0–75.0) | 48.0 (10.0–78.0) | 0.489 |
| Sex | 0.948 | ||
| Male | 126 (90.0%) | 522 (90.6%) | |
| Female | 14 (10.0%) | 54 (9.4%) | |
| Hepatitis B virus infection | 0.799 | ||
| No | 33 (23.6%) | 164 (28.5) | |
| Yes | 107 (76.4%) | 412 (71.5%) | |
| HBsAg | 0.912 | ||
| No | 14 (10%) | 62 (10.8%) | |
| Yes | 126 (90%) | 514 (89.2%) | |
| Tumor diameter | 8.0 (0.0–18.0) | 8.0 (0.0–32.0) | 0.078 |
| No# of tumor | 0.940 | ||
| Single | 122 (87.1%) | 498 (86.5%) | |
| Multiple | 18 (12.9%) | 78 (13.5%) | |
| PVTT | 0.963 | ||
| I | 46 (32.9%) | 193 (33.5%) | |
| II | 94 (67.1%) | 383 (66.5%) | |
| Encapsulation | 0.026 | ||
| No | 87 (62.1%) | 341 (59.2%) | |
| Incomplete | 9 (6.4%) | 85 (14.8%) | |
| Complete | 44 (31.5%) | 150 (26.0%) | |
| Liver Cirrhosis | <0.001 | ||
| No | 21 (15.0%) | 189 (32.8%) | |
| Yes | 119 (85.0%) | 387 (67.2%) | |
| Ascites | 0.368 | ||
| No | 120 (85.7%) | 512 (88.9%) | |
| Yes | 20 (14.3%) | 64 (11.1%) | |
| Esophageal and gastric varices | 0.458 | ||
| No | 109 (77.9%) | 467 (81.1%) | |
| Yes | 31 (22.1%) | 109 (18.9%) | |
| Child-Pugh | 0.750 | ||
| A | 138 (98.6%) | 562 (97.6%) | |
| B | 2 (1.4%) | 14 (2.4%) | |
| Satellite lesions | 0.011 | ||
| None | 11 (7.9%) | 34 (5.9%) | |
| Same lobe | 117 (83.6%) | 432 (75.0%) | |
| Different lobe | 12 (8.6%) | 110 (19.1%) | |
| Thickness of splenic hilum | 5.0 (4.1–15.0) | 3.2 (1.0–4.0) | <0.001 |
| TBIL | 15.0 (5.3–32.0) | 14.0 (4.0–251.0) | 0.768 |
| DBIL | 6.0 (2.1–16.0) | 6.6 (1.0–174.0) | 0.215 |
| ALB | 41.50 (30.0–52.0) | 41.7 (30.0–52.0) | 0.637 |
| ALT | 47.0 (11.0–262.0) | 43.0 (10.0–523.0) | 0.947 |
| PT | 12.5 (0.0–112.0) | 12.1 (0.0–212.5) | 0.928 |
| GGT | 119.0 (0.0–1052.0) | 125.0 (0.0–1052.0) | 0.508 |
| ALP | 107.5 (46.0–372.0) | 109.5 (0.0–595.0) | 0.673 |
| AFP | 1,210.0 (0.0–1,210.0) | 1,210.0 (0.0–3,400.0) | 0.297 |
| CA199 | 17.2 (0.0–235.6) | 23.0 (0.0–1,000.0) | 0.045 |
| CEA | 2.0 (0.0–12.0) | 2.2 (0.0–75.2) | 0.048 |
| AST | 47.0 (14.9–390.0) | 48.0 (14.9–389.0) | 0.628 |
| PLT | 141.0 (40.0–400.0) | 158.0 (0.0–495.0) | <0.001 |
Data were presented as n (%) or medians with interquartile range (IQR). PSM, propensity score matching; HBsAg, Hepatitis B surface antigen; PVTT, portal vein tumor thrombus; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALB, Albumin; ALT, Alanine Aminotransferase; PT, Prothrombin time; GGT, γ-Glutamyltransferase; ALP, Alkaline phosphatase; AFP, α-fetoprotein; CA199, Carbohydrate Atigen 19-9; CEA, Carcinoembryonic antigen; AST, Aspartate Aminotransferase; PLT, Platelet.